DEBRA Research Supports Eliksa Therapeutics in Developing ELK-003 for EB-Related Eye Conditions

DEBRA Research GmbH has announced an investment in Eliksa Therapeutics to further the development of ELK-003, a biological eye drop aimed at treating ocular complications associated with Epidermolysis Bullosa (EB). The investment will support the clinical development of ELK-003, currently in a pilot study with DEBRA Chile, involving 18 patients with no reported drug-related side effects among eight who completed treatment.

The initiative is part of a collaborative effort, including other mission-driven organizations such as Abe Fund and EB Research Partnership, focused on advancing treatments for this rare genetic disorder. ELK-003 features a unique amniotic fluid formulation designed to protect and repair the corneal surface, addressing severe eye complications faced by EB patients.